Cart
×
Pluristem Reports Data Showing PLX -PAD Cells Effective in Treating Duchenne Muscular Dystrophy
Santhera’s Marketing Authorization Application for Raxone® in Duchenne Muscular Dystrophy (DMD) Validated by the European Medicines Agency
FIRST PATIENT ENROLLED IN SUMMIT’S PhaseOut DMD, A PHASE 2 CLINICAL TRIAL OF EZUTROMID IN BOYS WITH DMD
Marathon Pharmaceuticals Announces Submission of Deflazacort New Drug Application to the FDA
CRISPR Therapeutics and Anagenesis Biotechnologies Announce Strategic In-Licensing and Collaboration Agreement to Develop CRISPR/Cas9-based Cell Therapies for Muscle Diseases
Sarepta Therapeutics Announces FDA Request For Dystrophin Data Prior To Making A Decision on Eteplirsen NDA
Idebenone reduces respiratory complications in patients with Duchenne muscular dystrophy